Production (Stage)
Eledon Pharmaceuticals, Inc.
ELDN
$2.87
-$0.13-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.85% | 58.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.26% | 20.41% | |||
| Operating Income | 27.26% | -20.41% | |||
| Income Before Tax | 85.30% | -157.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 85.44% | -157.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 85.44% | -157.97% | |||
| EBIT | 27.26% | -20.41% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 85.91% | -157.02% | |||
| Normalized Basic EPS | 86.70% | -142.70% | |||
| EPS Diluted | 85.91% | -89.38% | |||
| Normalized Diluted EPS | 86.70% | -145.60% | |||
| Average Basic Shares Outstanding | 10.42% | 34.46% | |||
| Average Diluted Shares Outstanding | 10.42% | 25.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||